• 1
    Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(9859):20952128.
  • 2
    Murray CJL, Vos T, Lozano R et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(9859):21972223.
  • 3
    The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:15811587.
  • 4
    Hacke W, Kaste M, Bluhmki E et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359:13171329.
  • 5
    Lees KR, Bluhmki E, von Kummer R et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375(9727):16951703.
  • 6
    Schumacher HC, Bateman BT, Boden-Albala B et al. Use of thrombolysis in acute ischemic stroke: analysis of the Nationwide Inpatient Sample 1999 to 2004. Ann Emerg Med 2007; 50:99107.
  • 7
    Hill MD, Buchan AM. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005; 172:13071312.
  • 8
    Wahlgren N, Ahmed N, Dávalos A et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369:275282.
  • 9
    Nakagawara J, Minematsu K, Okada Y et al. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010; 41:19841989.
  • 10
    Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann Intern Med 2002; 137:511520.
  • 11
    Heuschmann PU, Kolominsky-Rabas PL, Roether J et al. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. JAMA 2004; 292:18311838.
  • 12
    Bateman BT, Schumacher HC, Boden-Albala B et al. Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the nationwide inpatient sample 1999 to 2002. Stroke 2006; 37:440446.
  • 13
    Yamaguchi T, Mori E, Minematsu K et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006; 37:18101815.
  • 14
    Ohta T, Waga S, Handa W, Saito I, Takeuchi K. New grading of level of disordered consiousness (author's transl). No Shinkei Geka 1974; 2:623627.
  • 15
    Shigematsu K, Nakano H, Watanabe Y. The eye response test alone is sufficient to predict stroke outcome – reintroduction of Japan Coma Scale: a cohort study. BMJ Open 2013; 3:e002736.
  • 16
    Ono K, Wada K, Takahara T, Shirotani T. Indications for computed tomography in patients with mild head injury. Neurol Med Chir (Tokyo) 2007; 47:291297, discussion 297–8.
  • 17
    Saposnik G, Webster F, O'Callaghan C, Hachinski V. Optimizing discharge planning: clinical predictors of longer stay after recombinant tissue plasminogen activator for acute stroke. Stroke 2005; 36:147150.
  • 18
    Cuzick J. A Wilcoxon-type test for trend. Stat Med 1985; 4:8790.
  • 19
    Adams HP, del Zoppo G, Alberts MJ et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atheros. Stroke 2007; 38:16551711.
  • 20
    Minematsu K, Toyoda K, Hirano T et al. Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society. J Stroke Cerebrovasc Dis 2013; 22:571600.
  • 21
    Saver JL, Fonarow GC, Smith EE et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA 2013; 309:24802488.
  • 22
    Strbian D, Soinne L, Sairanen T et al. Ultra early thrombolysis in acute ischemic stroke is associated with better outcome and lower mortality. Stroke 2010; 41:712716.
  • 23
    Ronning OM, Guldvog B. Stroke units versus general medical wards, I: twelve- and eighteen-month survival: a randomized, controlled trial. Stroke 1998; 29:5862.
  • 24
    Inoue T, Fushimi K. Stroke care units versus general medical wards for acute management of stroke in Japan. Stroke 2014; 44:31423147.
  • 25
    Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev 2013; (9):CD000197.
  • 26
    Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M. Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology 2012; 79:306313.
  • 27
    Hacke W, Kaste M, Fieschi C et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352(9136):12451251.
  • 28
    Ovbiagele B, Saver JL. Day-90 acute ischemic stroke outcomes can be derived from early functional activity level. Cerebrovasc Dis 2010; 29:5056.